Rivaroxaban - StatPearls - NCBI Bookshelf
2023年4月17日 · Rivaroxaban was the first orally dosed, direct Factor Xa inhibitor, a small-molecule oxazolidinone derivative. It binds directly and reversibly to Factor Xa via the S1 and S4 pockets. Rivaroxaban competitively inhibits Factor Xa, demonstrating more than 10,000-fold selectivity for Factor Xa than other related serine proteases.
Rivaroxaban: Uses, Interactions, Mechanism of Action - DrugBank …
Pharmacology Indication. Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary ...
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban …
Rivaroxaban produces a pharmacodynamic effect that is closely correlated with its plasma concentration. The pharmacokinetic and pharmacodynamic relationship for inhibition of Factor Xa activity can be described by an E max model, and prothrombin time prolongation by …
利伐沙班 - 维基百科，自由的百科全书
利伐沙班（英语：Rivaroxaban），以Xarelto等品牌销售，是一种用于治疗和预防血栓的抗凝药物（血液稀释剂）。 具体而言，它用于治疗深静脉血栓形成和肺栓塞，并预防心房颤动和髋关节或膝关节手术后的血栓。 它是口服的。 [6]常见的副作用包括出血。 [6] 其他严重的副作用可能包括脊髓 …
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban ...
2014年10月28日 · The approved rivaroxaban dose schedule (15 mg twice daily for 3 weeks followed by 20 mg once daily) was derived based on pharmacological data from the clinical development programme to achieve a strong antithrombotic effect in the acute treatment phase and address the need to balance efficacy and bleeding risk for long-term treatment with a ...
(PDF) Rivaroxaban - Metabolism, Pharmacologic Properties and …
2017年5月18日 · Background: Rivaroxaban represents a selective direct inhibitor of activated coagulation factor X (FXa) having peroral bioavailability and prompt onset of action. Objective: The absorbtion of...
Rivaroxaban, an oral, direct factor Xa inhibitor, is a small molecule drug capable of inhibiting not only free factor Xa with high selectivity but also prothrombinase- bound and clot-associated factor Xa in a concentration-dependent manner.
Pharmacodynamic and pharmacokinetic basics of rivaroxaban
Rivaroxaban has been found to have a predictable clinical pharmacology profile providing the basis for the use of a fixed-dose regimen with no need for dose adjustment irrespective of age, weight and gender, essentially eliminating the need for routine coagulation monitoring.
Rivaroxaban - Metabolism, Pharmacologic Properties and …
This review discusses the properties, drug interactions, pharmacokinetics and clinical indications of rivaroxaban. Method: Dosing regimen of rivaroxaban was derived from pharmacologic data of the development program aimed to gain strong antithrombotic drug and balance between efficacy and risk of bleeding in patients. Results of doseranging ...
Rivaroxaban - an overview | ScienceDirect Topics
Rivaroxaban (Xarelto) is an orally administered reversible factor Xa inhibitor that selectively blocks the active site of factor Xa. Rivaroxaban is an oxazolidinone derivate that has structural similarity with antibiotic linezolid, but rivaroxaban has no antibacterial activity.